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Pffects of High-Dose Atorvastatin on
erebrovascular Events in Patients With Stable Coronary
isease in the TNT (Treating to New Targets) Study
avid D. Waters, MD, FACC,* John C. LaRosa, MD,
hilip Barter, MD, Jean-Charles Fruchart, PHD, Antonio M. Gotto, JR, MD, DPHIL, FACC,
oddy Carter, MD, Andrei Breazna, PHD, John J. P. Kastelein, MD, PHD, Scott M. Grundy, MD, PHD
an Francisco, California; New York, New York; Sydney, Australia; Lille, France;
msterdam, the Netherlands; and Dallas, Texas
OBJECTIVE We sought to assess the effects on cerebrovascular events of treating patients with stable coronary
disease with low-density lipoprotein cholesterol (LDL-C) levels substantially below 100 mg/dl.
BACKGROUND Lowering LDL-C with statins has been shown to reduce the risk of stroke in patients with
stable coronary disease. In observational studies, naturally low cholesterol levels have been
associated with an increased risk of hemorrhagic stroke. The cerebrovascular benefits of
treating patients with stable coronary disease to LDL-C levels substantially below 100 mg/dl
have not been previously investigated.
METHODS We describe an analysis of cerebrovascular events in the Treating to New Targets study, a trial
where 10,001 patients with documented coronary disease were randomized to treatment with
atorvastatin at 10 mg/day or 80 mg/day and followed for a median of 4.9 years.
RESULTS Mean LDL-C levels were 101 mg/dl on 10 mg atorvastatin and 77 mg/dl on 80 mg. In
addition to the reduction in major cardiovascular events (hazard ratio 0.78, 95% confidence
interval [CI] 0.69 to 0.89; p  0.0002), the primary end point of the trial, patients in the
80-mg arm experienced a reduction in cerebrovascular events (hazard ratio 0.77, 95% CI 0.64
to 0.93; p  0.007) and stroke (hazard ratio 0.75, 95% CI 0.59 to 0.96; p  0.02). Each
1-mg/dl reduction in LDL-C with treatment was associated with a 0.6% relative risk
reduction in cerebrovascular events (p  0.002) and a 0.5% relative risk reduction in stroke
(p  0.041). The incidence of hemorrhagic stroke was similar in the 80-mg and 10-mg
groups, 16 and 18 respectively, and the hemorrhagic strokes were distributed evenly across
quintiles of achieved LDL-C during treatment.
CONCLUSIONS Among patients with established coronary disease, treating to an LDL-cholesterol substan-
tially below 100 mg/dl with 80 mg/day atorvastatin reduces both stroke and cerebrovascular
events by an additional 20% to 25% compared with the 10 mg/day dose. An increase in
hemorrhagic stroke was not seen at low LDL-C levels. (Treating to New Targets;
http://www.clinicaltrials.gov; NCT00327691). (J Am Coll Cardiol 2006;48:1793–9)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.07.041© 2006 by the American College of Cardiology Foundation
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Ahe incidence of cerebrovascular events in Western coun-
ries appears to be at least as high as the incidence of
oronary events (1). Furthermore, the long-term outcome
fter even a minor ischemic stroke or transient ischemic
ttack (TIA) is bleak; for example, in a recent report of a
arge cohort study from the Netherlands, 60% of patients
ied and 54% had had at least one other vascular event over
mean follow-up period of 10 years (2).
The relationship between blood cholesterol levels and stroke
s not as clear as the relationship between cholesterol and
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ifferences emerge when strokes are classified as to type. An
ncreased rate of hemorrhagic stroke has been reported in
ubjects with naturally low cholesterol levels (4–7), but the
ncidence of ischemic stroke is increased at higher cholesterol
evels in the same populations (7,8).
Although earlier clinical trials did not show a reduction in
troke with cholesterol lowering (9), statins have reduced stroke or
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High-Dose Atorvastatin and Cerebrovascular Events November 7, 2006:1793–9erebrovascular events in randomized placebo-controlled trials in a
ariety of different patient populations (10–16). Whether statins
educe stroke by LDL-C reduction or primarily through other
echanisms is controversial (17–19).
The TNT (Treating to New Targets) study randomized
0,001 patients with documented coronary disease to ator-
astatin at 10 mg/day or 80 mg/day and followed them for
median of 4.9 years (20). The primary end point of TNT,
composite of coronary death, nonfatal myocardial infarc-
ion (MI), resuscitated cardiac arrest, and fatal or nonfatal
troke, was reduced in the 80-mg compared with the 10-mg
rm (hazard ratio 0.78, 95% confidence interval [CI] 0.69 to
.89; p  0.0002). In addition to fatal or nonfatal stroke
eing a component of the predefined primary end point of
he trial, a cerebrovascular event, defined as fatal or nonfatal
troke or TIA, was a predefined secondary end point.
erein we report in detail the results of TNT with respect
o stroke and cerebrovascular events.
ETHODS
he design of the TNT study has been previously described in
etail (20,21). Eligible patients were men and women 35 to 75
ears of age who had clinical evidence of coronary disease, either
revious MI or coronary revascularization, or previous or current
ngina with objective evidence of coronary disease. Patients with
DL-C levels between 130 and 250 mg/dl and triglycerides
600 mg/dl off lipid-lowering treatment were eligible to enter an
-week run-in period where they received 10mg/day atorvastatin.
hosewith anLDL-C level130mg/dlwere randomly assigned
o double-blind therapy with either 10 mg or 80 mg atorvastatin
er day. Follow-up visits occurred at week 12 and at months 6, 9,
nd 12, then every 6 months thereafter. Patients were questioned
t each visit about interim events or hospitalizations, and hospital
ecords were obtained.
tudy end points. The primary predefined outcome was the
ccurrence of a major cardiovascular event, defined as death
rom coronary heart disease, nonfatal nonprocedure-related
I, resuscitated cardiac arrest, or fatal or nonfatal stroke.
econdary outcomes were a major coronary event (the primary
nd point without stroke), a cerebrovascular event, hospitaliza-
ion for congestive heart failure, peripheral artery disease, death
rom any cause, any cardiovascular event, and any coronary
vent.
An independent end points committee consisting of 5
ardiologists adjudicated all potential end points in a blinded
ashion. They defined stroke as the rapid onset of a persistent
rain deficit thought to be due to obstruction or rupture in the
Abbreviations and Acronyms
LDL-C  low-density lipoprotein cholesterol
MI  myocardial infarction
TIA  transient ischemic attack
TNT  Treating to New Targetsrterial system and not secondary to brain trauma, tumor, or anfection. The deficit must have lasted longer than 24 h unless
eath intervened or unless there was a persistently demonstra-
le lesion that was consistent with the deficit. Patients admit-
ed with symptoms of developing stroke who were given tissue
lasminogen activator (TPA) with subsequent resolution of
ymptoms were also classified as stroke. Strokes occurring
uring surgery were also included.
Stroke were categorized as ischemic, hemorrhagic, em-
olic, or unknown, using the criteria developed for the
ystolic Hypertension in the Elderly Program (22). Strokes
ere classified as ischemic when one of the following
riteria was met: 1) a focal brain deficit without evidence by
omputerized tomography (CT), magnetic resonance imag-
ng (MRI), or lumbar puncture of blood, with the exception
f a mottled cerebral pattern, either decreased density by
T in a compatible location, or a negative CT or MRI, or
one done; 2) surgical or autopsy evidence of ischemic
nfarction; 3) symptoms of stroke followed by TPA with
esolution of symptoms; or 4) symptoms lasting 24 h but
ith a CT or MRI showing an infarct or hemorrhage in a
ocation to explain the findings.
Strokes were classified as hemorrhagic when there was: 1)
lood in the subarachnoid space or intraparenchymal hem-
rrhage by CT or MRI scan; 2) bloody spinal fluid by
umbar puncture; or 3) surgical or autopsy evidence of
emorrhage as the cause of the clinical syndrome. Strokes
ere classified as embolic when that was the likely diagnosis
e.g., in the presence of atrial fibrillation). Strokes were
lassified as unknown when the available data were insuffi-
ient for classification into one of the other categories. A
IA was defined as an event that persisted for 24 h with
documented focal neurologic deficit; the symptoms had to
e typical, such as transient unilateral blindness, a speech
eficit, or transient hemiparesis.
tatistical analyses. Cholesterol inclusion/exclusion crite-
ia were selected to achieve an average level of 100 mg/dl in
he 10 mg/day atorvastatin arm. To reach an average
DL-C level in the comparator group of approximately 75
g/dl, 80 mg/day atorvastatin was chosen. All analyses were
erformed on an intention-to-treat basis. End points were
nalyzed from the time of the first dose of study drug to the
rst event according to the Kaplan-Meier method. Differ-
nces between the 80-mg and 10-mg treatment groups were
ased on log rank analyses of the first occurrence of an end
oint during the 4.9-year follow-up period in each group.
elative risks, hazard ratios, and their 95% CIs were calculated
n univariate and multivariate models using the Cox regression
ith one or more predictors in the samemodel. Note that Cox
egression models allow for the predictor to be continuous
ariables (like on-treatment LDL-C) or dichotomous. Pro-
ortions were compared using the Fisher exact test.
ESULTS
atient population. A total of 18,469 patients were screened
t 256 sites in 14 countries; of these, 15,464 patients entered
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November 7, 2006:1793–9 High-Dose Atorvastatin and Cerebrovascular Eventshe open-label run-in period and 10,001 were randomized to
ouble-blind treatment with either 10 or 80 mg/day atorva-
tatin, as previously described (20,21). Of the 8,468 patients
ho did not enter the randomized phase of the study, 7,639
ad exclusion criteria, including 96 with elevated hepatic
nzymes1.5 times the upper limit of normal while taking 10
g/day atorvastatin and 727 with LDL-C levels 130 mg/dl
r triglycerides 600 mg/dl. Among the other 827 patients
ho were screened but not randomized, 16 died and 195 had
schemic events during the run-in period; 197 had other
dverse events, including myalgia in 35. The remaining 419
atients either did not comply with treatment or were elimi-
ated for a variety of administrative reasons. Two patients who
ere randomized but never given drug were also excluded.
atients were followed for a median of 4.9 years after random-
zation, during which time 38 patients in the 10-mg group and
5 in the 80-mg group were lost to follow-up.
The baseline features of the 2 treatment groups were well
alanced, and are listed in Table 1. Of note, 5.2% of the
atients had a history of a cerebrovascular accident, blood
ressure was well controlled, and 86.5% were receiving aspirin.
hanges in lipid levels and blood pressure. During the
un-in period on 10 mg/day atorvastatin, LDL-C levels
ecreased by 35% from a mean of 152 to a mean of 98
g/dl. Mean LDL-C levels during the study were 101
g/dl in the 10-mg arm of the trial and 77 mg/dl in the
Table 1. Baseline Features of the Study Patien
Ator
Age (yrs)
Male
Caucasian race
Body mass index
Systolic blood pressure (mm Hg)
Diastolic blood pressure (mm Hg)
Risk factors
Current smoker
Former smoker
Hypertension
Diabetes
Previous myocardial infarction
Previous cerebrovascular accident
Peripheral arterial disease
History of heart failure
History of CABG
History of PCI
Medication
Aspirin
Beta-blocker
ACE inhibitor
Angiotensin receptor blocker
Diuretic
Lipid levels (mg/dl)*
Total cholesterol
LDL cholesterol
HDL cholesterol
Triglycerides
*Lipid levels at baseline at the end of the run-in period with
ACE  angiotensin-converting enzyme; CABG  coronary art
low-density lipoprotein; PCI  percutaneous coronary intervention0-mg arm, and total cholesterol levels were 178 mg/dl and
50 mg/dl, respectively. Mean high-density lipoprotein
holesterol levels were 47 mg/dl in both treatment arms.
ean triglyceride levels were 156 mg/dl in the 10-mg arm
nd 132 mg/dl in the 80-mg arm.
At baseline, mean systolic and diastolic blood pressures were
dentical in the 2 treatment groups: systolic 131 17 mm Hg
nd diastolic 78 10mmHg. At last follow-up, systolic blood
ressure had decreased by 1.2  15.4 mm Hg in the 10-mg
rm and by 1.2  15.1 mm Hg in the 80-mg arm; diastolic
ressure decreases were 0.7  9.3 mm Hg in both groups.
lood pressures were very similar in the 2 treatment groups
hroughout the study.
erebrovascular events. During the follow-up period, 272
atients (2.7%) experienced a stroke, including 30 who expe-
ienced a fatal stroke. A TIA occurred in 197 patients, and a
otal of 448 (4.5%) experienced a cerebrovascular event (stroke
r TIA). As shown in Table 2, stroke was reduced in the
0-mg compared with the 10-mg group (hazard ratio 0.75,
5% CI 0.59 to 0.86; p 0.021). Cerebrovascular events were
lso reduced in the 80-mg arm (hazard ratio 0.77, 95%CI 0.64
o 0.93; p  0.007). The Kaplan-Meier curves for these end
oints are depicted in Figure 1. Among patients without a
istory of cerebrovascular disease (who comprised 95% of the
tudy population), fewer strokes occurred in the 80-mg com-
ared with the 10-mg group: 101 versus 128 (2.1% vs. 2.8%,
in 10 mg/day
5,006)
Atorvastatin 80 mg/day
(n  4,995)
 8.8 61.2  8.8
(80.8%) 4,054 (81.2%)
(94.1%) 4,699 (94.1%)
 4.7 28.4  4.5
 17 131  17
 10 78  10
(13.4%) 669 (13.4%)
(63.3%) 3,155 (63.2%)
(54.4%) 2,692 (53.9%)
(15.0%) 748 (15.0%)
(57.7%) 2,945 (59%)
(5.3%) 255 (5.1%)
(11.4%) 603 (12.1%)
(8.1%) 377 (7.6%)
(46.7%) 2,316 (46.4%)
(54.3%) 2,688 (53.8%)
(86.3%) 4,332 (86.7%)
(53.4%) 2,702 (54.1%)
(27.2%) 1,352 (27.1%)
(5.5%) 252 (5.0%)
(14.8%) 695 (13.9%)
 24 175  25
 18 97  18
 11 47  11
 72 151  70
nts receiving atorvastatin 10 mg/day.ts
vastat
(n 
60.9
4,045
4,711
28.6
131
78
672
3,167
2,721
753
2,888
263
570
404
2,338
2,719
4,321
2,675
1,362
275
742
175
98
47
151
patie
ery bypass graft; HDL  high-density lipoprotein; LDL 
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High-Dose Atorvastatin and Cerebrovascular Events November 7, 2006:1793–9azard ratio 0.79, 95% CI 0.61 to 1.02; p  0.070). Fewer
erebrovascular events also occurred at the higher dose among
atients without a history of cerebrovascular disease: 171 versus
12 (3.6% vs. 4.5%, hazard ratio 0.80, 95% CI 0.66 to 0.98; p
0.032).
The types of stroke in each treatment group are listed in
able 3. Overall, 54% of the strokes were ischemic, 25%
ere embolic, 12% were hemorrhagic, and in 9% the cause
as unknown. For each type of stroke the incidence was
ower in the 80-mg group than in the 10-mg group.
redictors of cerebrovascular events. The factors that
ere associated with a first cerebrovascular event are listed
n Table 4. The factors predictive of stroke (not shown) are
imilar to those predictive of cerebrovascular events. The
DL-C level at the screening visit was not a predictor of
erebrovascular events during the study, but LDL-C level
n treatment at 3 months was. Each 1-mg/dl reduction in
DL-C was associated with a 0.6% relative risk reduction in
erebrovascular events (p  0.002) and a 0.5% relative risk
eduction in stroke (p  0.041).
vents according to attained LDL-C level. Patients in
oth treatment groups were divided into quintiles according to
heir LDL-C levels at 3 months, as depicted in Table 5.
atients in the lowest quintile had LDL-C levels of 64
g/dl, with a mean of 54 mg/dl. A stepwise reduction in major
ardiovascular events was seen from the highest to the lowest
uintile of from 11.9% to 7.7% (p 0.0001). A similar pattern
as seen for cerebrovascular events (p  0.002) and stroke (p
0.041). The number of hemorrhagic strokes in each quintile,
rom lowest to highest, was 6, 5, 6, 9, and 7 (p  NS).
ortality rate in patients with cerebrovascular events.
mong the 518 patients with a history of cerebrovascular
isease at baseline, the mortality rate during the 4.9 years of
he study was 11.0%, compared with 5.4% in the 9,483
atients without a history of cerebrovascular disease at
aseline (p  0.0001). Among the 448 patients experienc-
ng a cerebrovascular event during the follow-up period, 69
f them (15.4%) subsequently died.
afety. During the run-in period, with 15,464 patients taking
0 mg/day atorvastatin, the drug was stopped because of
able 2. Event Rates and Hazard Ratios for Study End Points
End Point
Atorvastatin 10 mg/day
(n  5,006)
troke 155 (3.1%)
IA 110 (2.2%)
erebrovascular event 252 (5.0%)
ajor CV event* 548 (10.9%)
HD death 127 (2.5%)
onfatal MI 308 (6.2%)
ajor coronary event† 418 (8.3%)
ny coronary event‡ 1,326 (26.5%)
ny CV event§ 1,677 (33.5%)
Major cardiovascular event (primary end point) includes CHD death, nonfatal nonpr
HD death, nonfatal nonprocedure-related MI, and resuscitated cardiac arrest. ‡Any
rocedure-related MI, or documented angina. §Any cardiovascular event is defined
CHD  coronary heart disease; CI  confidence interval; CV  cardiovascular;yalgia in 35 cases and because of alanine transaminase (ALT) tnd/or aspartate aminotransferase (AST) elevations 1.5
imes the upper limit of normal in 96 cases. During the 4.9
ears of study follow-up, treatment-related adverse events
ccurred in 406 patients in the 80-mg group and in 289
atients in the 10-mg group (8.1% vs. 5.8%; p  0.001).
yalgia was reported in 241 patients in the 80-mg arm and in
34 patients in the 10-mg arm (4.8% vs. 4.7%; p  0.72).
onsecutive ALT and/or AST elevations 3 times the upper
imit of normal were seen in 60 patients in the 80-mg arm and
n 9 patients in the 10-mg arm (1.2% vs. 0.2%; p 0.001). No
atient experienced consecutive creatine kinase elevations10
imes the upper limit of normal.
ISCUSSION
his study provides evidence that reducing LDL-C levels with
0 mg/day atorvastatin to levels well below 100 mg/dl in
atients with stable coronary disease reduces the incidence of
troke and all cerebrovascular events. The relative risk reduc-
ions in cerebrovascular events and coronary events are similar.
n increase in the incidence of hemorrhagic stroke was not
een either at the high dose of atorvastatin or at the lowest
chieved LDL-C levels during treatment.
revious studies. Randomized, placebo-controlled statin tri-
ls have shown a reduction in cerebrovascular events as well as
oronary events in patients with stable coronary disease (10–
2) as well as in patients with unstable coronary disease (13),
ypertension (14), high coronary risk (15), and diabetes
16). The Cholesterol Treatment Trial collaborators have
ecently reported a prospective meta-analysis of 90,056
atients from 14 randomized statin trials (23). Overall, fatal
r nonfatal stroke was reduced by 17% (95% CI 12% to
2%). There was a trend toward greater proportional reduc-
ions in stroke with greater LDL-C reduction (p  0.009).
The TNT study differs from previous statin trials because 2
oses of the same statin were compared and because a lower
DL-C level, a mean of 77mg/dl, wasmaintained over amedian
f 4.9 years in the 80-mg atorvastatin arm. The TNT study
emonstrates that additional benefit for stroke and other impor-
vastatin 80 mg/day
(n  4,995)
Hazard Ratio
(95% CI) p Value
117 (2.3%) 0.75 (0.59–0.96) 0.021
87 (1.7%) 0.79 (0.60–1.05) 0.099
196 (3.9%) 0.77 (0.64–0.93) 0.007
434 (8.7%) 0.78 (0.69–0.89) 0.0002
101 (2.0%) 0.80 (0.61–1.03) 0.087
243 (4.9%) 0.78 (0.66–0.93) 0.004
334 (6.7%) 0.80 (0.69–0.92) 0.0019
1,078 (21.6%) 0.79 (0.73–0.86) 0.0001
1,405 (28.1%) 0.81 (0.75–0.87) 0.0001
re-related MI, resuscitated cardiac arrest, and stroke. †Major coronary event includes
ary event is defined as a major coronary event, coronary revascularization procedure,
coronary event, stroke, or TIA.
myocardial infarction; TIA  transient ischemic attack.Ator
ocedu
coronant vascular end points can be achieved with the highest dose of
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November 7, 2006:1793–9 High-Dose Atorvastatin and Cerebrovascular Eventspotent statin, reducing LDL-Cwell below the traditional target
f 100 mg/dl.
The TNT study does not address the issue of whether statin
herapy reduces the risk of cerebrovascular events in patients
ith previous cerebrovascular events but without known cor-
nary disease. The SPARCL (Stroke Prevention by Aggressive
eduction in Cholesterol Levels) study, comparing placebo to
0 mg/day atorvastatin in 4,731 patients with a previous stroke
r TIA, recently demonstrated that the high dose of atorva-
tatin significantly reduced both stroke and coronary events in
his population (24).
echanism of benefit. The reductions in stroke and
Figure 1. Kaplan-Meier curves for serebrovascular events in the 80-mg arm were not due to a seduction in blood pressure, because both systolic and
iastolic pressures were identical in the treatment arms
hroughout the study. However, each 1-mg/dl change in
n-treatment LDL-C was associated with a 0.6% change in
he risk of a cerebrovascular event (p  0.002) and a 0.5%
hange in the risk of stroke (p  0.041). Expressed in terms
f treatment groups, LDL-C was 24% lower in the 80-mg
rm, stroke was 25% lower, and cerebrovascular events were
3% lower. The relationship of LDL-C changes to stroke is
imilar to what has been reported in meta-analyses of
lacebo-controlled statin trials (23).
Cholesterol lowering with statins has been shown to
(A) and cerebrovascular events (B).tabilize carotid artery plaques in patients undergoing ca-
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High-Dose Atorvastatin and Cerebrovascular Events November 7, 2006:1793–9otid endarterectomy (25) and to slow the progression of
arotid atherosclerosis as assessed by B-mode ultrasound
26). Most ischemic strokes are caused by thromboemboli
rom the carotid arteries or the aortic arch. Statins may
nterfere with the thrombotic component of ischemic stroke
y inducing beneficial effects on the coagulation cascade
27) and by correcting the increased thrombogenic potential
f platelets that is associated with hyperlipidemia (28).
Statins also induce an impressive variety of beneficial
ffects that are independent of cholesterol lowering. A
imitation of many studies in this area is the difficulty in
istinguishing between causation and just a statistical cor-
elation. In the cerebral endothelium and parenchyma,
tatins regulate nitric oxide synthase to reduce platelet and
eukocyte adhesion and activation, increase vasodilation and
educe postischemic permeability (18). Statins also exert
ntiinflammatory and antioxidant effects that are neuropro-
ective in cerebral ischemia and stroke (18). In different
odent models statins have been shown to reduce the
everity of stroke through these mechanisms (18).
ow cholesterol and hemorrhagic stroke. Naturally low
lood cholesterol levels have been associatedwith an increased risk
f hemorrhagic stroke in different geographic populations (4–7).
n theMultiple Risk Factor Intervention Trial, a study of 350,977
iddle-aged men with no history of MI or diabetes at baseline,
eath from intracranial hemorrhage was 3-fold higher in those
ith total cholesterol levels below 160mg/dl at baseline (7).Most
f the patients in the 80-mg arm of the TNT study, where the
ean total cholesterol throughout the study was 150 mg/dl
compared with 178mg/dl in the 10mg arm), would fall into this
Table 3. Types of Stroke in Treatment Group
Atorvastatin 10 mg/
(n  5,006)
Fatal and nonfatal stroke 155 (3.1%)
Embolic 44 (0.9%)
Ischemic 90 (1.8%)
Hemorrhagic 18 (0.4%)
Unknown 15 (0.3%)
Values expressed as number of patients (%).
able 4. Factors Predictive of Cerebrovascular Events
Variable Patients (%) HR (95% CI), Un
erebrovascular disease 517 (5.2) 3.38 (2.60–4.4
iabetes 1,501 (15) 2.35 (1.91–2.8
ypertension 5,412 (54) 1.94 (1.59–2.3
ge older than 65 yrs 3,809 (38) 1.92 (1.59–2.3
ongestive heart failure 781 (7.8) 1.72 (1.30–2.2
DL-C at 3 months† 9,769 (98) 1.006 (1.002–1.
DL-C change†‡ 9,762 (98) 0.997 (0.993–1.
ender (female) 1,902 (19) 1.23 (0.98–1.5
evascularization 4,654 (47) 1.22 (0.92–1.6
DL-C at screening† 9,994 (100) 1.003 (0.998–1.
DL-C at end of run-in† 9,993 (100) 1.001 (0.999–1.
ever smoked 2,338 (23) 1.09 (0.88–1.3
yocardial infarction 5,833 (58) 1.05 (0.87–1.2
First all predictors were used in the multivariate model; predictors with p  0.1 wer
n LDL-C from screening (off medication) to 3 months of treatment on study drug.
CI  confidence interval; HDL-C  high-density lipoprotein cholesterol; HR  hazaow-cholesterol high-risk group. An increased risk of hemorrhagic
troke was not seen, however, either in the 80-mg arm or in the
owest quintile of on-treatment LDL-C (64 mg/dl).
The relative risk of hemorrhagic stroke for statin-treated versus
lacebo patients in the Cholesterol Treatment Trialists Collabo-
ators meta-analysis is 1.05 (95% CI 0.78 to 1.41) (23). In the
PARCL study (24), high-dose atorvastatin reduced stroke over-
ll; however, hemorrhagic stroke, albeit uncommon, occurred
ore frequently in the atorvastatin group (p  0.02). Taken
ogether, these data suggest that it is unlikely that high-dose
tatins increase the risk of hemorrhagic stroke in most subsets of
atients. Whether some patients with previous stroke are at
ncreased risk for hemorrhagic stroke with statin therapy requires
urther study.
tudy limitations. The criteria used to define stroke and
he categories of stroke selected by the end points commit-
ee differ from the generally accepted criteria, and the end
oints committee did not include a neurologist. The find-
ngs of this study apply to patients with stable coronary
isease. The study population was overwhelmingly Cauca-
ian, and 20% were women. Extrapolation of these results
o other populations should be done with caution. Although
he incidence of hemorrhagic stroke was not increased at
ower LDL-C levels, the number of these events is not
ufficient to detect a small increase in risk.
Despite these limitations, the results of TNT demonstrate that
owering LDL-C considerably below 100mg/dl using 80mg/day
torvastatin provides additional clinical benefit, including a reduc-
ion in stroke and cerebrovascular events. The reduction in
erebrovascular events and overall stroke, without an observed
Atorvastatin 80 mg/day
(n  4,995)
Total Patients
(n  10,001)
117 (2.3%) 272 (2.7%)
29 (0.6%) 73 (0.7%)
68 (1.4%) 158 (1.6%)
16 (0.3%) 34 (0.3%)
11 (0.2%) 26 (0.3%)
te p Value HR (95% CI), Multivariate* p Value
0.0001 2.60 (1.99–3.42) 0.0001
0.0001 1.94 (1.57–2.39) 0.0001
0.0001 1.63 (1.32–2.00) 0.0001
0.0001 1.70 (1.40–2.05) 0.0001
0.0002 — —
0.002 1.006 (1.002–1.010) 0.0014
0.043 — —
0.07 — —
0.18 — —
0.25 — —
0.43 — —
0.44 — —
0.63 — —
removed. †Hazard ratio calculated for each 1 mg/dl difference in LDL-C. ‡Changes
dayivaria
0)
8)
7)
1)
9)
01)
000)
3)
2)
008)
005)
5)
6)
e thenrd ratio; LDL-C  low-density lipoprotein cholesterol.
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reat coronary patients more aggressively.
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